Baxter’s Rixubis Receives FDA Approval for Treating Hemophilia

by Kathy Jones on  June 28, 2013 at 8:37 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The US Food and Drug Administration revealed that it has approved Baxter's genetically engineered protein, Rixubis, for treating patients suffering from a form of the chronic blood disorder hemophilia.
 Baxter’s Rixubis Receives FDA Approval for Treating Hemophilia
Baxter’s Rixubis Receives FDA Approval for Treating Hemophilia

Figures released by the National Hemophilia Foundation reveals that hemophilia B is the second most common type of hemophilia and affects around 25,000 people across the globe.

The condition is caused when the patients fail to produce enough quantity of blood clotting factor needed for natural control of bleeding. Rixubis is the first new treatment approved in the last 15 years for treating hemophilia and is to be administered twice weekly.

"Rixubis is a welcome addition to our leading portfolio of hemophilia treatments, providing a much-needed treatment option for the thousands of people living with hemophilia B. This approval moves us one significant step forward in our pursuit of a bleed-free world, one patient at a time", the president of Baxter's BioScience business, Ludwig Hantson said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Genetic Counseling von Willebrand Disease Bleeding Disorders Hemophilia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive